[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stem-cell-transplantation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,72,111,134,180,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644426","prospective-observational-study-of-outcomes-after-gemcitabine-docetaxel-melphalan-and-carboplatin-with-autologous-stem-cell-transplantation-in-pediatric-relapsedrefractory-germ-cell-tumors-100644426",false,"NCT07662018","Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed\u002FRefractory Germ Cell Tumors","Inclusion Criteria\n\n* Male or female participants, greater than 1 month of age up to 21 years old. Neonates (birth to 1 month of age) will not be enrolled on this protocol.\n* Participants with relapsed\u002Frefractory seminomatous or nonseminomatous GCT who undergo an autologous stem cell transplantation (ASCT) with conditioning therapy including gemcitabine, docetaxel, melphalan, carboplatin (GemDMC) for germ cell tumors\n* As part of our analysis, we will also include participants aged 0-21 years old who have previously underwent ASCT with GemDMC\n* Participants who receive the following regimen:\n\nHigh dose chemotherapy (HDC) course #1:\n\nGemcitabine\u002FDocetaxel\u002FMelphalan\u002FCarboplatin D-6 Admission and start hydration D-5 Gemcitabine 1,500 mg\u002Fm2 IV Docetaxel 275 mg\u002Fm2 IV D-4 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-3 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-2 Gemcitabine 1,500 mg\u002Fm2 IV Melphalan 20 mg\u002Fm2 IV Carboplatin 250 mg\u002Fm2 IV D-1 Rest D0 Stem Cell infusion\n\nFollowed by HDC course #2 consisting of:\n\nHigh-dose course #2: Carboplatin\u002FEtoposide D-6 Admission and start hydration D-5 to -3 Etoposide 750 mg\u002Fm2 IV Carboplatin 700 mg\u002Fm2 IV D-2 Rest D-1 Rest D0 Stem Cell infusion\n\nExclusion Criteria\n\n* Participants who do not or did not receive GemDMC as part of the conditioning regimen for an ASCT are not eligible for this study","ALL","21 Years",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","To collect information about treatment outcomes in pediatric and adolescent patients with relapsed\u002Frefractory germ cells tumors who receive GemDMC with an ASCT.",[23,24,25,26,27,28,29,30],"Prospective Observational Study","Gemcitabine","Docetaxel","Melphalan","Carboplatin","Stem Cell Transplantation","Pediatric Relapsed","Refractory Germ","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":35},"2026-06-05",{"date":39,"type":19},"2033-12-31",{"name":41,"class":42},"M.D. Anderson Cancer Center","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100629049","ehealth-mindfulness-based-music-therapy-intervention-for-patients-undergoing-stem-cell-transplantation-100629049","NCT07469592","eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation","Inclusion Criteria:\n\n* ≥ 18 years of age\n* have a primary diagnosis of a hematologic malignancy (e.g., myelodysplastic syndrome \\[MDS\\], acute myeloid leukemia \\[AML\\], acute lymphoblastic leukemia \\[ALL\\], or non Hodgkin's Lymphoma \\[NHL\\])\n* have a treatment plan for a hematopoietic stem cell transplant\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* history of severe psychiatric illness (e.g., psychosis, active suicidality, inpatient treatment in the past 12 months)\n* severe cognitive impairment (per the short portable mental status questionnaire)\n* hearing impairment\n* active alcohol or substance dependence within the past six months\n* participated in the prior pilot MBMT R61 phase\n* participated in music therapy or mindfulness programs in the past six months","18 Years",{"count":52,"type":19},165,"INTERVENTIONAL",[55],"NA","The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and reduce symptom burden and disease activity in patients undergoing stem cell transplantation.",[28,58,59,60,61],"Myelodysplastic Syndromes","Leukemia, Myeloid, Acute","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Lymphoma, Non-Hodgkin","NOT_YET_RECRUITING","2026-04-10",{"date":65,"type":35},"2026-04-13",{"date":67,"type":19},"2026-06-30",{"date":69,"type":19},"2028-06-30",{"name":71,"class":42},"University of Miami",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":53,"phases":84,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100621612","phase-1-granulocyte-augmented-cord-blood-transplantation-for-poor-risk-leukaemia-100621612","NCT07372885","GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia","A Multi-centre Phase I\u002FII Trial of Granulocyte-augmented Cord Blood Transplantation for Young Adults With Very Poor Risk Acute Myeloid Leukaemia.","GRACE","INCLUSION CRITERIA:\n\n1. Availability of a suitable cord blood unit\n2. Age between 16 and 55 years\n3. Primary diagnosis of Acute Myeloid Leukaemia (AML) or MDS\u002FAML (as defined by ICC 2022) fitting one or more of the following criteria:\n\n   * TP53 mutation (single- or multi-hit)\n   * Presence of inv(3) (q21.3q26.2) or t(3;3)(q21.3;q26.2)\n   * Adverse risk (as per ICC 2022) and \\>0.1% MRD by flow cytometry after 2 cycles of induction\n   * AML (any risk) with partial remission (\\\u003C10% blasts) after 2 cycles induction\n   * Early relapse (\\\u003C6 months) after chemotherapy alone (excluding t(16;16), inv(16) or t(8;21))\n4. Bone marrow performed within 28 days of starting conditioning chemotherapy demonstrates either:\n\n   * \\\u003C10% blasts\n   * \\>10% blasts with a hypocellular background (must be discussed with the trial team)\n5. Suitable fitness and organ function as per the following criteria:\n\n   * Glomerular filtration rate \\>50 mL\u002Fmin\u002F1.73m2\n   * Ejection fraction \\>50%\n   * FEV1 \\>65% without dyspnoea on mild activity\n   * AST\u002FALT \\\u003C3 x ULN\n   * Bilirubin \\\u003C1.5 x ULN (excluding Gilbert's syndrome)\n   * Performance Status (ECOG) of 0 or 1\n6. Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must agree to use appropriate, highly effective, contraception from the point of commencing therapy until 12 months after transplant\n\nEXCLUSION CRITERIA:\n\n1. AML Secondary to a myeloproliferative neoplasm\n2. Active CNS disease\n3. Prior allogeneic stem cell transplant\n4. Participation in another clinical trial that would alter any aspect of the transplant protocol or that aims to reduce the subsequent risk of relapse (discuss with trial team if unsure)\n5. History of cardiac arrhythmia\n6. Ischaemic heart disease, valvular heart disease or congestive cardiac failure\n7. Transient ischaemic attack or cerebrovascular accident\n8. Rheumatologic disease (SLE, RA, polymyositis, mixed CTD or polymyalgia rheumatica)\n9. Ulcerative colitis or Crohn's disease\n10. Liver cirrhosis\n11. Presence of an active second malignancy\n12. Uncontrolled infection, including viral reactivation (CMV, EBV)\n13. HIV positive\n14. Hepatitis B\u002FC active infection with measurable viral load (patients with chronic hepatitis B or C infection require clear documentation of absence of cirrhosis by either fibroscan or biopsy, regardless of viral load)\n15. Pregnancy, breastfeeding, unwilling to use contraception\n16. Contraindications to administration of pooled granulocytes\n17. Previous history of sensitivity to granulocytes\n18. Inability of patient to give informed consent\n19. Any other organ dysfunction or co-morbidity that precludes transplant in the opinion of the investigator\n20. Any concern by PI","16 Years","55 Years",{"count":83,"type":19},50,[85,86],"PHASE1","PHASE2","Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death. Patients with certain mutations and those transplanted without first clearing their disease have very poor outcomes with most relapsing soon after transplant, and then surviving only a few months. A recent trial at the Royal Manchester Children's Hospital used cord blood stem cells alongside a type of white blood cell called 'granulocytes' and produced surprisingly good outcomes for children with very resistant leukaemia.\n\nGRACE is a clinical trial for adults (\\\u003C55 years) with Acute Myeloid Leukaemia that has not responded to chemotherapy or harbours mutations that predict a very poor response to conventional transplant. Participants will receive a transplant using umbilical cord blood and be given additional infusions of white blood cells, called granulocytes. The trial will be split into two parts:-The first will study the safety of this new approach. The experience of the investigators in children is that granulocyte infusions cause a fever, rash and expansion of another type of white blood cell called lymphocytes. Children that did not have this reaction did not respond to treatment. The investigators therefore believe that the reaction is necessary for the treatment to work, but the investigators must ensure that it is safe in adult patients. The trial design allows the investigators to determine the dose of granulocytes that is best tolerated and most likely to be effective.\n\nThe aim of the second part is to demonstrate that the new treatment is more effective than conventional transplantation.\n\nThe study will be conducted in three NHS transplant centres. Patients will be recruited over 36 months and followed up for a minimum of 1 year. The study is funded by Blood Cancer UK.",[89,28,90,91,92],"Acute Myeloid Leukemia","Stem Cell Transplantation, Hematopoietic","Cord Blood Stem Cell Transplantation","Cellular Therapy",[94,95,96,97,98,99,100],"Grace","granulocyte-augmented cord blood transplantation","poor risk acute myeloid leukaemia","Cord Blood Transplantation","Myelodysplastic Syndrome","TP53","MECOM","2026-03-10",{"date":103,"type":35},"2026-03-11",{"date":105,"type":19},"2026-02-09",{"date":107,"type":19},"2029-12-31",{"name":109,"class":42},"University of Manchester",3,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":53,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":43},"100573222","a-clinical-study-of-ultra-transplantation-for-the-treatment-of-major-thalassemia-scheme-100573222","NCT06743477","A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme","Clinical Study Protocol for Ultra-transplantation for the Treatment of Eastern Mediterranean Major","UTTS","Patient inclusion criteria :\n\n* Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types;\n* Age between 7-12 years old, male or female not limited; Weight\\\u003C40kg\n* The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell transplantation treatment; And patients who unconditionally or refuse to undergo gene therapy for thalassemia;\n* There are HLA matched or mismatched donors who meet the donor criteria through physical examination;\n* The patient and their family agree to receive super transplantation treatment and sign a written informed consent form before the transplantation trial.\n\n  （2） Exclusion criteria for patients:\n* Psychiatric patients;\n* Participants in clinical trials of other drugs within the past month;\n* There are no suitable HLA mismatched donors available.\n* Other researchers have determined that they are not suitable to participate in this study.\n\n  （3） Supplier screening criteria:\n* HLA typing matches the patient's haplotype\n* KIR configuration\n* NIMA\n* DSA negative\n* Routine physical examination\n* Genetic screening for carriers of thalassemia, mild or no carriers of thalassemia\n* Sign the informed consent form.","7 Years","12 Years",{"count":122,"type":19},5,[55],"Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy. Under the guidance of Professor Ai, the center plans to carry out clinical research on hypertransplantation and explore safe and effective new therapies for thalassemia.",[28],"2025-08-29",{"date":128,"type":35},"2025-09-02",{"date":126,"type":19},{"date":131,"type":19},"2026-12-31",{"name":133,"class":42},"Hu Peng",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":143,"studyType":20,"phases":4,"briefSummary":144,"conditions":145,"keywords":156,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100569332","fertility-protection-for-children-adolescents-and-young-adults-100569332","NCT06692868","Fertility Protection for Children, Adolescents and Young Adults","FeProCAYA","Children, adolescents, young adults with a diagnosis of cancer before the age of 21 years\n\nor\n\nChildren, adolescents, young adults undergoing SCT for a malignant or non-malignant condition before the age of 21 years\n\ntreated at the Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.",{"count":142,"type":19},2000,"20 Years","This study focuses on improving fertility preservation and long-term care for children, adolescents, and young adults (CAYA) undergoing cancer treatments or stem cell transplantation. These treatments can harm fertility, and ensuring that patients receive the right support and follow-up care is critical.\n\nThe main study goals are:\n\n1. Understanding Fertility Risks: Researchers aim to identify factors that predict fertility problems after cancer treatments, such as the type of therapy, hormone levels, body composition, or genetic predispositions.\n2. Addressing Patient and Family Needs: The program will explore the concerns, needs, and challenges faced by young patients and their parents regarding fertility. It will also examine how these issues affect their quality of life.\n3. Improving Clinical Care: Current practices in fertility preservation and counseling will be studied to identify gaps and improve care structures.\n\nTo achieve these goals, the program will:\n\n* Create a database to collect and analyze medical data from patients before, during, and after cancer treatments.\n* Study the prevalence and long-term effects of fertility problems in young patients.\n* Document medical interventions like fertility preservation methods (e.g., freezing eggs or sperm) and treatments for late effects.\n* Assess patients' and families' fertility-related quality of life and their informational needs.\n\nUltimately, the project aims to establish an interdisciplinary center to support fertility preservation and improve the quality of care for young patients facing cancer and its treatments.",[146,28,147,148,149,150,151,152,153,154,155],"Stem Cell Transplant","Oncological Outcomes","Oncological Patients","Oncological Children","Fertility","Fertility Protection","Endocrinological Late-effects","Paediatric Oncology","CAYA","Survivors",[139,157,158,159,160,161,162,163,164,165,166,167,168,169,170,154],"Fertility protection","Endocrinological follow-up after oncological disease","children","fertility","adolescents","young adults","TYA","teenagers and young adults","paediatric oncology","follow-up care","endocrinological late-effects","survivors","stem cell transplant","stem cell transplantation","2025-01-13",{"date":173,"type":35},"2025-01-16",{"date":175,"type":35},"2024-12-09",{"date":177,"type":19},"2044-11",{"name":179,"class":42},"University of Ulm",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":50,"enrollmentInfo":188,"targetDuration":4,"studyType":53,"phases":190,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":210},"100475950","phase-3-studying-conditioning-regimen-in-pediatric-transplantation---aml--script-aml-100475950","NCT05477589","Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML","A Randomized, Multi-Center Phase III Trial Comparing Two Conditioning Regimens (CloFluBu and BuCyMel) in Children With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.","SCRIPT-AML","Inclusion criteria for randomization part of the study:\n\n* Age ≤18 years at time of initial AML, age ≤ 21 years at transplantation.\n* HCT is performed in a study participating center\n* All women of childbearing potential who have to have a negative pregnancy test within 2 weeks prior to the start of treatment.\n* Signed informed consent.\n* Any relapsed AML after initial treatment according to a defined international AML protocol. (NOPHO-DBH AML 2012\u002Fnew protocol), or AML in first remission with transplant indications and treatment according to national AML protocol (NOPHO-DBH AML 2012 or new protocol).\n* In hematological remission, defined as:\n\n\\\u003C 5 % leukemic blasts confirmed by flow cytometry (in patients with an informative leukemia associated immunophenotype) in a bone marrow sample taken ≤14 days prior to start of conditioning and no evidence of extramedullary disease, including in CNS and no leukemic blasts in the peripheral blood (verified by flow cytometry in case immature cells are detected in the peripheral blood differential).\n\n-Patients must have a related or unrelated donor fulfilling any of the following criteria: HLA 10\u002F10 allelic matched, identical, sibling BM donor or HLA 10\u002F10 or 9\u002F10 allelic matched related\u002Funrelated BM or PBSC donor orHLA 5-6\u002F6 unrelated or 6-7-8\u002F8 unrelated Cord Blood (UCB)\n\nInclusion criteria for observation\u002Fregistration only:\n\n* Diagnosis of acute myeloid leukemia\n* Indication for allogeneic stem cell transplantation, as defined by primary treatment protocol or treating physician.\n* Age ≤18 years at time of initial AML, age ≤ 21 years at transplantation.\n* Not eligible for randomization, either due to lack of consent or not fulfilling inclusion criteria for interventional part of the study.\n* Signed informed consent to prospectively register follow-up data.\n\nExclusion criteria for the randomization part of the study :\n\n* Diagnosis of myelodysplastic syndrome (MDS).\n* Diagnosis of juvenile myelomonocytic leukemia (JMML).\n* History of previous malignancy (AML diagnosed as secondary cancer).\n* Known diagnosis of Fanconi anemia.\n* Prior autologous or allogeneic hematopoietic stem cell transplant.\n* Planned prophylactic DLI or other immunotherapeutic interventions after HCT that are not included in the upfront protocol, Planned anti-leukemic medication after HCT that are not included in the upfront protocol\n* Known intolerance to any of the chemotherapeutic drugs in the protocol.\n* Major organ failure precluding administration of planned chemotherapy.\n* Patients with uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.\n* Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion, e.g. malformation syndromes, cardiac malformations, metabolic disorders, renal impairment (\\\u003C30% of normal glomerular filtration rate), severe pulmonary, hepatic or cardiac impairment due to toxicity or infection.\n* Karnofsky \u002F Lansky score \\\u003C 50%\n* Females who are pregnant (positive serum or urine βHCG) or breastfeeding.\n* Females of childbearing potential or men who have sexual contact with females of childbearing potential unwilling to use effective forms of birth control or abstinence for one year after transplantation.\n* Subjects unwilling or unable to comply with the study procedures.\n\nExclusion criteria for the observational part of the study:\n\n* Diagnosis of Myelodysplastic syndrome (MDS).\n* Diagnosis of Juvenile myelomonocytic leukemia (JMML).\n* Age above 21 years at time of transplantation\n* No consent is given to prospectively register outcome data\n* Prior autologous or allogeneic hematopoietic stem cell transplant.",{"count":189,"type":19},170,[191],"PHASE3","It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)",[194,28],"Acute Myeloid Leukemia (AML) in Remission",[196,59,197,198,199],"Leukemia","Neoplasms","Haematopoietic cell transplantation","Paediatric","2024-12-16",{"date":202,"type":35},"2024-12-19",{"date":204,"type":35},"2022-06-07",{"date":206,"type":19},"2031-12-31",{"name":208,"class":209},"Vastra Gotaland Region","OTHER_GOV",17,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":221,"conditions":222,"keywords":225,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":43},"100555000","rehabilitation-needs-for-hematologic-cancer-candidate-for-hematopoietic-stem-cell-transplantation-or-car-t-cell-therapy-100555000","NCT06506396","Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy","Outcomes and Rehabilitation Needs of Patients With Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy: a Prospective Observational Study","HEMATOneeds","Inclusion Criteria:\n\n* Patients with hematologic cancer scheduled to undergo HSCT or CAR T-cell therapy;\n* Age ≥18 years\n* Able to provide informed consent to participate in the study\n* Able to understand and participate in the study\n* Able to understand and communicate in the Italian language\n\nExclusion Criteria:\n\n• Patients who are unable to perform physical tests or have contraindications to movement",{"count":220,"type":19},20,"Hematopoietic Stem Cell Transplantation (HSCT) and CAR T-cell therapy are effective treatments for blood cancers, extending patients lives. However, these treatments can cause side effects like muscle weakness and fatigue. Recent findings suggest these issues can significantly affect patient quality of life during CAR T-cell therapy.\n\nPatients undergoing HSCT and CAR T-cell therapy often face frequent infections and strong immune responses, requiring long periods of rest. This worsens their physical condition and impacts their quality of life, muscle strength, and fatigue levels. Minimizing these side effects is crucial to improve the well-being of patients undergoing these advanced treatments.\n\nThis study aims to assess the physical abilities (main goal) of patients preparing for HSCT or CAR T-cell therapy. It also aims to examine their quality of life and describe the symptoms and complications they may experience. The results will help identify rehabilitation needs for these patients.",[28,223,224],"Immunotherapy","CAR T-Cell Therapy",[226,227,228,229,230],"Functional Status","Quality of life","Needs Assesment","Physical Conditioning, Human","Hematologic Neoplasms","2024-07-17",{"date":233,"type":35},"2024-07-19",{"date":235,"type":19},"2024-08",{"date":237,"type":19},"2025-05",{"name":239,"class":42},"University of Modena and Reggio Emilia"]